Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 340 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Lazertinib December 4, 2024 Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later... September 30, 2020 September 11, 2001 – Strength is Not Always Unyielding September 11, 2021 FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... December 3, 2024 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Pembrolizumab Cancer Survivor And His Organ Donor Run NYC Marathon Together To... Cancer in My Community: Striving to Lead People to Cancer Care... Tips from Your Cancer Care Team – Coping with Treatment During...
